98%
921
2 minutes
20
Purpose: Past studies emphasize positive associations between parental opioid misuse and adverse outcomes for children and families yet neglect to understand whether opioid misuse interferes with positive parenting behaviors, such as checking on homework or engaging in serious discussions with an adolescent child.
Method: We analyzed data collected from parent-adolescent dyads (N = 24,900) surveyed for the 2014-2019 National Survey on Drug Use and Health, specifically examining relationships between parents' past-year opioid misuse or heroin use and adolescent-reported parenting behaviors.
Results: For both mother-child and father-child dyads, parent-reported opioid misuse was significantly associated with only one of 10 positive parenting behaviors. Mothers who reported misusing opioids helped with homework less often (p = .04) and fathers who reported misusing opioids had less frequent engagement in serious conversations with their adolescent children (p = .04). Having longer conversations with children about substance use was positively associated with mother-reported opioid misuse (p = .013), mother-reported heroin use (p < .001), and father-reported heroin use (p < .001).
Discussion: These data provide insight into existing deficits and strengths of parents who have misused opioids in the past and present opportunities to intervene in the family unit to disrupt cycles of intergenerational substance misuse. Our findings reframe positive parenting as an attainable goal for parents who have misused opioids and inform the development of interventions designed to address distinct deficits experienced in mothers and fathers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jadohealth.2025.06.020 | DOI Listing |
Cochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDFSubst Use Addctn J
October 2025
Partnered Evidence-based Policy Resource Center, Boston VA Healthcare System, Boston, MA, USA.
Objectives: To estimate the effect of the passage of state laws targeting patient brokering on opioid-related outcomes.
Background: In response to growing awareness of unethical substance use disorder (SUD) treatment practices, several states in the United States have passed laws targeting patient brokering and deceptive marketing. Patient brokering and deceptive marketing laws are intended to reduce the chances individuals with SUD interact with bad actors or suffer from adverse outcomes related to inappropriate SUD treatment, but the effectiveness of these laws is unknown.
Subst Use Addctn J
October 2025
Health Economics Resource Center, VA Palo Alto Health Care System, Palo Alto, CA, USA.
Background: To address the opioid use disorder (OUD) public health crisis, the ADvancing Pharmacological Treatments for OUD (ADaPT-OUD) external facilitation randomized trial was conducted in 8 intervention and 27 matched control low-performing Veterans Health Administration (VHA) facilities to increase the prescribing of medications for OUD (MOUD). Facilities were considered low-performers if they were in the bottom quartile of the facility ratio of Veterans with OUD who received MOUD. The objective of this analysis was to evaluate the healthcare expenditures of Veterans with OUD who received care in ADaPT-OUD intervention facilities compared to those receiving care in matched control facilities.
View Article and Find Full Text PDFBMJ Open
September 2025
Faillace Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA.
Introduction: Exposure to prescription opioids following traumatic injury can increase the risk of developing tolerance, persistent opioid use and opioid use disorder. The mechanisms underlying opioid tolerance or dependence are not well understood, and no biomarkers predict risk. Opioid exposure causes epigenetic modifications, including alterations in microRNA (miRNA) expression.
View Article and Find Full Text PDFJ Opioid Manag
September 2025
Retired Addiction Physician and Psychiatrist, London SE1, United Kingdom. ORCID: https://orcid.org/0000-0002-5035-5833.
Despite the contribution of the µ-agonist fentanyl to the United States's opiate overdose epidemic, no human studies specifically address the ability of extended-release preparations of the opiate antagonist naltrexone (NTX) to block fentanyl's life-threatening µ-agonist-mediated respiratory depression. This paper presents three case histories of clinically necessary opiate challenges in opiate-abusing patients implanted with extended-release NTX (ER-NTX). It also reviews the sparse literature and is the first evidence that antagonist blood levels from ER-NTX preparations can completely block the lethal µ-agonist effects of at least 1,000 mcg of intravenous fentanyl.
View Article and Find Full Text PDF